Both drugs have shown promising efficacy in treating non-small cell lung cancer (NSCLC) and are structural derivatives of ARS-1620, a pioneering covalent inhibitor that selectively binds to the mutated cysteine in KRAS G12C (Jänne et al., 2022; Skoulidis et al., 2021). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.